Predicting asthma control and exacerbations: Chronic asthma as a complex dynamic model

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 3, 2007, Pages 223-230

  Frey, Urs ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Asthma; Fractals; Homeokinesis; Long range correlation; Prediction; Risk factors

Indexed keywords

CORTICOSTEROID; SALMETEROL;

ASTHMA; CONTROL STRATEGY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE MARKER; ENVIRONMENTAL FACTOR; EXPIRED AIR; FRACTAL ANALYSIS; HEREDITY; HUMAN; INFLAMMATION; LUNG FUNCTION; MATHEMATICAL ANALYSIS; MEDICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SPUTUM LEVEL; STATISTICAL ANALYSIS; THEORETICAL MODEL;

ASTHMA; CHRONIC DISEASE; HUMANS; LUNG; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 34248171701     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32810fd771     Document Type: Review

References (94)

1. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med 2000; 162:2341-2351.
2. NIH-NHLBI/WHO workshop report: Global strategy for asthma management and prevention (GINA); Jan 1995 (updated 2002). NIH Publication No. 02-3659.
3. Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999; 13:1198-1208.
4. Payne DN, Rogers AV, Adelroth E, et al. Early thickening of the reticular basement membrane in children with difficult asthma. Am J Respir Crit Care Med 2003; 167:78-82.
5. Saglani S, McKenzie SA. Environmental factors relevant to difficult asthma. Paediatr Respir Rev 2002; 3:248-254.
6. Fredberg JJ. Bronchospasm and its biophysical basis in airway smooth muscle. Respiratory research 2004; 5:2.
7. Plaza V, Serrano J, Picado C, Sanchis J. Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma. Eur Respir J 2002; 19:846-852.
8. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22:470-477.
9. Alvey Smaha D. Asthma emergency care: national guidelines summary. Heart Lung 2001; 30:472-474.
10. Bibi H, Nutman A, Shoseyov D, et al. Prediction of emergency department visits for respiratory symptoms using an artificial neural network. Chest 2002; 122:1627-1632.
11. Halonen M, Stern DA. Predicting the course of asthma. Allergy Asthma Proc 2006; 27:328-331.
12. Harrison B, Stephenson P, Mohan G, Nasser S. An ongoing confidential enquiry into asthma deaths in the Eastern Region of the UK, 2001-2003. Prim Care Respir J 2005; 14:303-313.
13. Kaza V, Bandi V, Guntupalli KK. Acute severe asthma: recent advances. Curr Opin Pulm Med 2007; 13:1-7.
14. McCarren M, McDermott MF, Zalenski RJ, et al. Prediction of relapse within eight weeks after an acute asthma exacerbation in adults. J Clin Epidemiol 1998; 51:107-118.
15. McCarren M, Zalenski RJ, McDermott M, Kaur K. Predicting recovery from acute asthma in an emergency diagnostic and treatment unit. Acad Emerg Med 2000; 7:28-35.
16. McCoy K, Shade DM, Irvin CG, et al. Predicting episodes of poor asthma control in treated patients with asthma. J Allergy Clin Immunol 2006; 118:1226-1233.
17. Miller MK, Lee JH, Blanc PD, et al. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J 2006; 28:1145-1155. Comprehensive overview of clinical risk factors related to asthma control in severe asthma.
18. Miller MK, Lee JH, Miller DP, Wenzel SE. Recent asthma exacerbations: A key predictor of future exacerbations. Respir Med 2007; 101:481-489.
19. Pilotto LS, Smith BJ, McElroy HJ, et al. Hospital attendance prediction tool also identifies impaired quality of life in adults with asthma in general practice. J Asthma 2003; 40:163-169.
20. Rasmussen F, Taylor DR, Flannery EM, et al. Risk factors for hospital admission for asthma from childhood to young adulthood: a longitudinal population study. J Allergy Clin Immunol 2002; 110:220-227.
21. Rodrigo G, Rodrigo C. A new index for early prediction of hospitalization in patients with acute asthma. Am J Emerg Med 1997; 15:8-13.
22. Rodrigo G, Rodrigo C. Early prediction of poor response in acute asthma patients in the emergency department. Chest 1998; 114:1016-1021.
23. ten Brinke A, Sterk PJ, Masclee AA, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26:812-818.
24. Twaddell SH, Henry RL, Francis JL, Gibson PG. The prediction of hospital admission in children with acute asthma. J Paediatr Child Health 1996; 32:532-535.
25. Bousquet J, Gaugris S, Kocevar VS, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Clin Exp Allergy 2005; 35:723-727.
26. Serrano J, Plaza V, Sureda B, et al. Alexithymia: a relevant psychological variable in near-fatal asthma. Eur Respir J 2006; 28:296-302.
27. Martinez-Moragon E, Plaza V, Serrano J, et al. Near-fatal asthma related to menstruation. J Allergy Clin Immunol 2004; 113:242-244.
28. Liard R, Perdrizet S, Reinert P. Wheezy bronchitis in infants and parents' smoking habits. Lancet 1982; 1:334-335.
29. Hanrahan JP, Tager IB, Segal MR, et al. The effect of maternal smoking during pregnancy on early infant lung function. Am Rev Respir Dis 1992; 145:1129-1135.
30. Gauderman WJ, McConnell R, Gilliland F, et al. Association between air pollution and lung function growth in southern California children. Am J Respir Crit Care Med 2000; 162 (4 Pt 1):1383-1390.
31. Gent JF, Triche EW, Holford TR, et al. Association of low-level ozone and fine particles with respiratory symptoms in children with asthma. JAMA 2003; 290:1859-1867.
32. Kunzli N, Kaiser R, Medina S, et al. Public-health impact of outdoor and trafficrelated air pollution: a European assessment. Lancet 2000; 356:795-801.
33. Cockcroft DW, Ruffin RE, Dolovich J, Hargreave FE. Allergen-induced increase in nonallergic bronchial reactivity. Clin Allergy 1977; 7:503-513.
34. Call RS, Ward G, Jackson S, Platts-Mills TA. Investigating severe and fatal asthma. J Allergy Clin Immunol 1994; 94 (6 Pt 1):1065-1072.
35. O'Hollaren MT, Yunginger JW, Offord KP, et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. New Engl J Med 1991; 324:359-363.
36. Csonka P, Kaila M, Laippala P, et al. Wheezing in early life and asthma at school age: predictors of symptom persistence. Pediatr Allergy Immunol 2000; 11:225-229.
37. Laan MP, Baert MR, Bijl AM, et al. Markers for early sensitization and inflammation in relation to clinical manifestations of atopic disease up to 2 years of age in 133 high-risk children. Clin Exp Allergy 2000; 30:944-953.
38. Newson R, Strachan D, Archibald E, et al. Acute asthma epidemics, weather and pollen in England, 1987-1994. Eur Respir J 1998; 11:694-701.
39. Kraft M, Cassell GH, Henson JE, et al. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med 1998; 158:998-1001.
40. ten Brinke A, van Dissel JT, Sterk PJ, et al. Persistent airflow limitation in adultonset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection. J Allergy Clin Immunol 2001; 107:449-454.
41. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol 1996; 98 (6 Pt 1):1016-1018.
42. Kuntz KM, Kitch BT, Fuhlbrigge AL, et al. A novel approach to defining the relationship between lung function and symptom status in asthma. J Clin Epidemiol 2002; 55:11-18.
43. Fuhlbrigge AL, Weiss ST, Kuntz KM, Paltiel AD. Forced expiratory volume in 1 s percentage improves the classification of severity among children with asthma. Pediatrics 2006; 118:347-355. Provides new evidence of the relationship between a simple lung function parameter and related symptoms in asthmatic children. Such simple lung function parameters can be easily assessed in clinical practice.
44. Zhang J, Yu C, Holgate ST, Reiss TF. Variability and lack of predictive ability of asthma end-points in clinical trials. Eur Respir J 2002; 20:1102-1109.
45. Tantisira KG, Fuhlbrigge AL, Tonascia J, et al. Bronchodilation and bronchoconstriction: Predictors of future lung function in childhood asthma. J Allergy Clin Immunol 2006; 117:1264-1271. Provides a new statistical model to investigate the relationship between changes in lung function following a drug challenge and related symptoms in asthma.
46. Sears MR, Greene JM, Willan AR, et al. A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. New Engl J Med 2003; 349:1414-1422.
47. Kitch BT, Paltiel AD, Kuntz KM, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004; 126:1875-1882.
48. Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001; 107:61-67.
49. Timonen KL, Schwartz J, Nielsen J, Brunekreef B. Associations between markers of respiratory morbidity in European children. Eur Respir J 2002; 19:479-486.
50. Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163:406-412.
51. Zacharasiewicz A, Wilson N, Lex C, et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 2005; 171:1077-1082.
52. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159 (4 Pt 1):1043-1051.
53. Mortimer KM, Redline S, Kattan M, et al. Are peak flow and symptom measures good predictors of asthma hospitalizations and unscheduled visits? Pediatr Pulmonol 2001; 31:190-197.
54. Jones SL, Kittelson J, Cowan JO, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001; 164:738-743.
55. Pijnenburg MW, Hofhuis W, Hop WC, et al. Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission. Thorax 2005; 60:215-218.
56. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233-242.
57. Latzin P, Kuehni CE, Baldwin DN, et al. Elevated exhaled nitric oxide in newborns of atopic mothers precedes respiratory symptoms. Am J Respir Crit Care Med 2006; 174:1292-1298. Highlights the predictive role of FeNO in newborns before onset of symptoms. Furthermore it provides first evidence that NO metabolism may be involved in the evolvement of respiratory disease even before the onset of clinical symptoms.
58. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-1721.
59. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000; 161:64-72.
60. Martin AJ, Campbell DA, Gluyas PA, et al. Characteristics of near-fatal asthma in childhood. Pediatr Pulmonol 1995; 20:1-8.
61. Mandhane PJ, Greene JM, Cowan JO, et al. Sex differences in factors associated with childhood- and adolescent-onset wheeze. Am J Respir Crit Care Med 2005; 172:45-54.
62. Sandford AJ, Chagani T, Zhu S, et al. Polymorphisms in the IL4, IL4RA, and FCERIB genes and asthma severity. J Allergy Clin Immunol 2000; 106 (1 Pt 1):135-140.
63. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. New Engl J Med 2006; 354:697-708. Important insight of the role of TNFa in severe asthma.
64. Cookson WO, Moffatt MF. Genetics of asthma and allergic disease. Hum Mol Genet 2000; 9:2359-2364.
65. Erzurum SC. Inhibition of tumor necrosis factor alpha for refractory asthma. New Engl J Med 2006; 354:754-758. Important insight of the role of TNFα in severe asthma.
66. Holgate ST, Yang Y, Haitchi HM, Powell RM, et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc Am Thorac Soc 2006; 3:440-443.
67. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60:1012-1018.
68. Pulleyn LJ, Newton R, Adcock IM, Barnes PJ. TGFbeta1 allele association with asthma severity. Hum Genet 2001; 109:623-627.
69. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. New Engl J Med 1992; 326:501-506.
70. Taylor DR, Drazen JM, Herbison GP, et al. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000; 55:762-767.
71. Taylor DR, Hancox RJ, McRae W, et al. The influence of polymorphism at position 16 of the beta2-adrenoceptor on the development of tolerance to beta-agonist. J Asthma 2000; 37:691-700.
72. Taylor DR, Kennedy MA. Genetic variation of the beta(2)-adrenoceptor: its functional and clinical importance in bronchial asthma. Am J Pharmacogenomics 2001; 1:165-174.
73. Taylor DR, Kennedy MA. Beta-adrenergic receptor polymorphisms and drug responses in asthma. Pharmacogenomics 2002; 3:173-184.
74. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaledbetaagonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48:134-138.
75. Wechsler ME, Lehman E, Lazarus SC, et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173:519-526.
76. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512.
77. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162:75-80.
78. Martinez FD. Safety of long-acting beta-agonists: an urgent need to clear the air. New Engl J Med 2005; 353:2637-2639.
79. Martinez FD. Serious adverse events and death associated with treatment using long-acting beta-agonists. Clin Rev Allergy Immunol 2006; 31(2-3):269-278.
80. Lemiere C, Malo JL, Gautrin D. Nonsensitizing causes of occupational asthma. Med Clin North Am 1996; 80:749-774.
81. Frey U, Brodbeck T, Majumdar A, et al. Risk of severe asthma episodes predicted from fluctuation analysis of airway function. Nature 2005; 438:667-670.
82. Fuhlbrigge AL. Asthma severity and asthma control: symptoms, pulmonary function, and inflammatory markers. Curr Opin Pulm Med 2004; 10:1-6.
83. Mandelbrot B. The fractal geometry of nature. San Francisco: Freeman; 1982.
84. Weibel ER. The pathway for oxygen: structure and function in the mammalian respiratory system. Cambridge: Harvard University Press; 1984.
85. Venegas JG, Winkler T, Musch G, et al. Self-organized patchiness in asthma as a prelude to catastrophic shifts. Nature 2005; 434:777-782.
86. Suki B, Barabasi AL, Hantos Z, et al. Avalanches and power-law behaviour in lung inflation. Nature 1994; 368:615-618.
87. Suki B. Fluctuations and power laws in pulmonary physiology. Am J Respir Crit Care Med 2002; 166:133-137.
88. Suki B, Frey U. Temporal dynamics of recurrent airway symptoms and cellular random walk. J Appl Physiol 2003; 95:2122-2127.
89. Frey U, Maksym GN, Silverman M, Suki B. New approaches to the understanding of complex chronic lung diseases. Eur Respir Monogr 2006; 37:345-360. A more detailed description of the behaviour of the complex respiratory system as outlined in this review for the interested reader. Description of structural and temporal fractal properties of the lung including long range correlations of lung function.
90. Que CL, Kenyon CM, Olivenstein R, et al. Homeokinesis and short-term variability of human airway caliber. J Appl Physiol 2001; 91:1131-1141.
91. Peng CK, Havlin S, Stanley HE, Goldberger AL. Quantification of scaling exponents and crossover phenomena in nonstationary heartbeat time series. Chaos 1995; 5:82-87.
92. Peng CK, Mietus J, Hausdorff JM, et al. Long-range anticorrelations and non-Gaussian behavior of the heartbeat. Phys Rev Lett 1993; 70:1343-1346.
93. van den Toorn LM, Overbeek SE, de Jongste JC, et al. Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med 2001; 164:2107-2113.
94. Taylor DR, Town GI, Herbison GP, et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax 1998; 53:744-752.